论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Liang Y, Tian B, Zhang J, Li K, Wang L, Han J, Wu Z
Received 1 September 2016
Accepted for publication 16 January 2017
Published 2 March 2017 Volume 2017:12 Pages 1699—1715
DOI https://doi.org/10.2147/IJN.S121262
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Akshita Wason
Peer reviewer comments 5
Editor who approved publication: Dr Lei Yang
Abstract: Gemcitabine (GEM) and paclitaxel (PTX) are effective combination anticancer
agents against non-small-cell lung cancer (NSCLC). At the present time, a main
challenge of combination treatment is the precision of control that will
maximize the combined effects. Here, we report a novel method to load GEM
(hydrophilic) and PTX (hydrophobic) into simplex tumor-targeted nanostructured
lipid carriers (NLCs) for accurate control of the ratio of the two drugs. We
covalently preconjugated the dual drugs through a hydrolyzable ester linker to
form drug conjugates. N -acetyl-D-glucosamine (NAG) is a
glucose receptor-targeting ligand. We added NAG to the formation of NAG-NLCs.
In general, synthesis of poly(6-O -methacryloyl-D-galactopyranose)–GEM/PTX
(PMAGP-GEM/PTX) conjugates was demonstrated, and NAG-NLCs were prepared using
emulsification and solvent evaporation. NAG-NLCs displayed sphericity with an
average diameter of 120.3±1.3 nm, a low polydispersity index of 0.233±0.04, and
accurate ratiometric control over the two drugs. A cytotoxicity assay showed
that the NAG-NLCs had better antitumor activity on NSCLC cells than normal
cells. There was an optimal ratio of the two drugs, exhibiting the best
cytotoxicity and combinatorial effects among all the formulations we tested. In
comparison with both the free-drug combinations and separately nanopackaged
drug conjugates, PMAGP-GEM/PTX NAG-NLCs (3:1) exhibited superior synergism.
Flow cytometry and confocal laser scanning microscopy showed that NAG-NLCs
exhibited higher uptake efficiency in A549 cells via glucose receptor-mediated
endocytosis. This combinatorial delivery system settles problems with
ratiometric coloading of hydrophilic and hydrophobic drugs for tumor-targeted
combination therapy to achieve maximal anticancer efficacy in NSCLC.
Keywords: polymer–drug conjugate, nanostructured
lipid carriers, combination treatment, ratiometric drug loading, cancer
targeting